
|Videos|September 3, 2017
Who is Not a Good Candidate for MRSA Prodrug TXA709?
Author(s)Contagion Editorial Staff
Daniel Pilch, PhD, explains which patients would not make good candidates for MRSA prodrug TXA709.
Advertisement
Daniel Pilch, PhD, associate professor, Rutgers Robert Wood Johnson Medical School, explains which patients would not make good candidates for MRSA prodrug TXA709. Dr. Pilch shares that TXA709 is capable of treating life-threatening bloodstream infections as well as skin and soft tissue infections. MRSA is also known for infecting bone; although distribution studies suggest that the drug can treat bone infections, more research still needs to be done.
Newsletter
Stay ahead of emerging infectious disease threats with expert insights and breaking research. Subscribe now to get updates delivered straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Contagion Live
1
Measles Update: February 6, 2026
2
Pritelivir Improves Outcomes in Immunocompromised Patients With Refractory Herpes Simplex Virus
3
HIV in the Black Community: Shifting from Stigma and Health Inequalities to Communication and Care Initiatives
4
Antibiotics Deconstructed: IV Fosfomycin
5
































































































































